Immunome climbs as Stifel initiates coverage
01/10/2026 13:27
BUZZ-Immunome climbs as Stifel initiates coverage ** Immunome IMNM.O shares up 1.85% premarket
** Stifel initiates oncology drugmaker's stock with "hold" rating
** Brokerage's $24 PT marks 11.6% upside to last close
** Experimental desmoid-tumor drug varegacestat hardly differs from rival SpringWorks' approved Ogsiveo in effectiveness, pain relief and convenience - Stifel
** Says advanced targeted cancer drugs, led by IM-1021, show promise but need more clinical results
** Those products deliver cancer-killing drugs directly to cancer cells, while limiting damage to healthy cells
** Average rating of 16 analysts is "buy"; median PT $35.50 - data compiled by LSEG
** IMNM largely flat YTD
(Reporting by Jayasree Prabhu)
Recent news on Immunome
See all newsBrief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage